Reporting of critical care trial abstracts: a comparison before and after the announcement of CONSORT guideline for abstracts by Akira Kuriyama et al.
RESEARCH Open Access
Reporting of critical care trial abstracts: a
comparison before and after the
announcement of CONSORT guideline
for abstracts
Akira Kuriyama*†, Naomi Takahashi† and Takeo Nakayama
Abstract
Background: An extension of the Consolidated Standards of Reporting Trials (CONSORT) statement provides a
checklist of items to improve the reporting quality of abstracts of randomized controlled trials (RCTs). However,
authors of abstracts in some fields have poorly adhered to this guideline. We did an extensive literature survey to
examine the quality of reporting trial abstracts in major critical care journals before and after announcement of the
CONSORT guideline for abstracts.
Methods: We reviewed abstracts of RCTs published in four major critical care journals with publication dates
ranging from 2006 to 2007 (pre-CONSORT) and from 2011 to 2012 (post-CONSORT): Intensive Care Medicine (ICM),
Critical Care (CC), American Journal of Respiratory and Critical Care Medicine (AJRCCM), and Critical Care Medicine
(CCM). For each item in the CONSORT guideline for abstracts, we considered that an abstract was well-reported
when it reported a relevant item and adhered to the guideline. Our primary outcomes were to describe the
proportion of abstracts that adhered to the guideline for each item in each period and the changes between the
two periods. Pearson’s chi-square analysis was performed to compare adherence to the guideline between the
two periods.
Results: Our inclusion criteria yielded 185 and 166 abstracts from pre- and post-CONSORT periods, respectively.
Less than 50% of abstracts adequately reported trial design (16.3%), participants (44.0%), outcomes in methods
(49.4%), randomization (1.8%), blinding (4.2%), numbers randomized (37.4%) and analyzed (8.4%), recruitment
(4.2%), outcomes in results (16.9%), harms (27.7%), trial registration (42.2%), and funding (13.9%) in the recent
period. There was significant improvement in reporting title, primary outcomes in both methods and results,
interventions, harms, trial registration, and funding between the two periods (p < 0.05). Improvements were seen
in reporting of participants in the Methods sections in CCM, as well as in outcomes in results and trial registration
in AJRCCM and CCM, between the two periods. A significant decline was noted in reporting of interventions in
Methods sections in AJRCCM and ICM, as well as the numbers randomized in Results sections in CC, over time.
Conclusions: Reporting of some items in abstracts for critical care trials improved over time, but the adherence
to the CONSORT guideline for abstracts was still suboptimal.
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Background
Randomized controlled trials (RCTs) are studies designed
to compare therapeutic or preventive interventions in
medicine. Clear, transparent, and sufficient abstracts are
required when reporting RCTs, because readers consider
articles reporting RCTs according to the information pro-
vided in abstracts. In particular, health professionals with
limited access to the full texts rely on abstracts, which
might eventually influence healthcare decisions [1, 2]. Ab-
stracts of conference proceedings are also important re-
sources in conducting systematic reviews, which would
otherwise introduce a form of bias if excluded [3].
An extension of the Consolidated Standards of Report-
ing Trials (CONSORT) published in 2008 provides a
checklist of items to be included in journal or confer-
ence abstracts reporting RCTs [4]. Overall, studies evalu-
ating the reporting quality of trial abstracts in other
fields have shown poor adherence to the CONSORT
guideline for abstracts since publication of the guideline
[5–14]. Some studies have also reported significant im-
provements in adherence, but still suboptimal adherence
to the guideline, comparing the situation before and
after publication of this guideline [15–17]. To date, little
is known about adherence to the CONSORT guideline
for abstracts or changes in the reporting of trial abstracts
from before to after the publication of this guideline in
the domain of critical care. In this study, we examined
the quality of reporting trial abstracts in major critical
care journals before and after announcement of the
CONSORT guideline for abstracts.
Methods
Study selection
We conducted a search of PubMed to identify all RCTs
published in major critical care journals before and after
the release of the CONSORT guideline for abstracts in
2008. We included critical care journals that focused on
general critical care topics, and we excluded those on
subspecialty or specific areas. As of 2006 and 2007,
American Journal of Respiratory and Critical Care Medi-
cine (AJRCCM), Intensive Care Medicine (ICM), Critical
Care Medicine (CCM), and Critical Care (CC) were the
general critical care journals that had the four highest
impact factors, provided by Thomson Reuters (New
York, NY, USA). We thus selected these four journals.
We selected two date ranges: pre-CONSORT from 2006
to 2007 and post-CONSORT from 2011 to 2012. We
selected these periods because an interval of at least 24
months was considered necessary for dissemination of
the reporting guidelines [16, 18], and previous similar
studies in other fields have employed similar periods
[16, 17]. The latest search was performed on 31 January
2015. Abstracts were included if they reported RCTs of
any design. If the abstract of a potentially relevant
article was unclear, we retrieved and assessed the full
text to see if the study reported an RCT. We excluded
abstracts of conference proceedings, observational stud-
ies, nonrandomized trials, quasi-RCTs, cost-effectiveness
studies, diagnostic studies, letters, editorials, and re-
views. We also excluded secondary and subgroup ana-
lyses of RCTs that had already been published.
Assessment of abstracts
Two authors (A.K. and N.T.) independently reviewed
abstracts and assessed each item of the CONSORT
checklist [4]. We conducted a pilot review of 60 articles,
and the uniformity of interpretation was thereby assured.
Through this pilot review, we found that the setting of
RCTs in the “Participants” section and the estimated
effect size for “Outcomes” in the Results section were
particularly underreported. This weakness was identified
in a previous study [16], and we therefore conducted an
additional assessment of these two items along with
existing items in the CONSORT for abstract guideline.
Occasionally, two items, such as “Registration” and
“Funding,” were described on the journal websites,
whereas they were not published in the PubMed record.
We therefore preferentially assessed the descriptions on
journal websites to overcome this discrepancy. For each
item, we deemed reporting adequate in an abstract only
when the abstract described the relevant item and fully
adhered to the explanation and elaboration of CONSORT
guideline for abstracts. We considered that an abstract was
underreporting or inadequately reporting when a relevant
item was either not reported or was not described as sug-
gested by the explanation and elaboration of the guideline.
Any disagreements were resolved by consensus decision,
and when a decision was hard to make, agreement was
reached through discussion with the third author (T.N.).
Statistical analyses
For each item, we determined the number of abstracts
that adhered to the CONSORT guideline for abstracts.
Next, we determined the proportion of such abstracts
among all included abstracts and subsequently determined
proportions by journal. Pearson’s chi-square analysis was
performed to compare adherence to the CONSORT
guideline for abstracts between the pre-CONSORT and
post-CONSORT periods for each item. Tests of statistical
significance were two-sided, and values of p < 0.05 were
considered significant. All analyses were conducted using
Stata version 12.1 software (StataCorp, College Station,
TX, USA).
Results
Our search yielded 227 and 215 abstracts from the pre-
CONSORT and post-CONSORT periods, respectively
(Table 1). After applying our inclusion and exclusion
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criteria, 185 and 166 abstracts in the pre-CONSORT
and post-CONSORT periods, respectively, were analyzed
(Fig. 1). These included 52 crossovers trials, 5 cluster-
randomized trials, 2 factorial trials, and 3 N-of-1 trials;
all others were parallel trials. Analyses by journal pro-
duced variable results with small numbers of abstracts;
as a result, combined results are mainly shown (Table 2).
Reporting of general items
Significantly more trials were described in the title as
“randomized” in the post-CONSORT period (56.6%)
than in the pre-CONSORT period (32.4%) (p < 0.01). A
small proportion of trials from both periods described
details of the trial design (pre-CONSORT 22.7%, post-
CONSORT 16.3%).
Reporting of trial methods
Participants were described in less than half of abstracts
in both periods (pre-CONSORT 41.1%, post-CONSORT
44.0%), due to inadequate reporting of the setting. Inter-
ventions were adequately described in both periods, but
a significant decrement in reporting of this item was
noted in the post-CONSORT period (pre-CONSORT
92.4% vs post-CONSORT 81.9%; p < 0.01). Trials from
both periods adequately described objectives or hypoth-
eses of the trials (pre-CONSORT 93.5%, post-
CONSORT 95.2%). Trials from both periods inad-
equately specified primary outcomes (pre-CONSORT
31.4%, post-CONSORT 49.4%), but a significant im-
provement was seen in the post-CONSORT period (p =
0.003). Randomization procedures and details regarding
blinding were poorly reported in both periods, with no
significant improvement in these items between periods.
Reporting of trial results
Numbers of participants randomized in each group, trial
status, and numbers of participants analyzed in each
group were poorly reported in both periods, and no sig-
nificant change was seen between periods. Primary out-
comes for each group were inadequately reported in
both periods, due to poor reporting of estimated effect
sizes and precision. A significant increment in reporting
of these items was noted in the post-CONSORT period
Table 1 The number of abstracts included in the analysis from
both periods
Journal Pre-CONSORT Post-CONSORT Total
AJRCCM 64 (35%) 45 (27%) 109 (31%)
CCM 66 (36%) 52 (31%) 118 (34%)
ICM 33 (18%) 34 (20%) 67 (19%)
CC 22 (12%) 35 (21%) 57 (16%)
Total 185 (100%) 166 (100%) 351 (100%)
Abbreviations: AJRCCM American Journal of Respiratory and Critical Care
Medicine, CC Critical Care, CCM Critical Care Medicine, CONSORT Consolidated
Standards of Reporting Trials, ICM Intensive Care Medicine
Fig. 1 Flowchart of article selection. CONSORT Consolidated Standards of Reporting Trials
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(p < 0.001). Important adverse effects or side effects were
also inadequately reported in both periods, although a sig-
nificant improvement was seen in the post-CONSORT
period (27.7%) (p < 0.001).
Reporting of trial conclusions
Trial conclusions were sufficiently reported in both periods
(pre-CONSORT 97.3%, post-CONSORT 97.0%).
Reporting of trial registration and funding
Reporting of trial registration and funding was signifi-
cantly improved in the post-CONSORT period compared
with the pre-CONSORT period (p < 0.01). However, the
frequency of adequate reporting of these items was still
suboptimal in the post-CONSORT period (42.2% and
13.9%, respectively).
Evaluations by journal
Noteworthy observations by journals are shown in Table 3.
Trial designs were reported in less than 20% of abstracts
across the journals, with CC being the lowest-reporting
journal. Reporting of participants in the Methods section
was adequate and improved over time in CCM but not in
the other journals. Reporting of interventions in Methods
sections declined in AJRCCM and ICM, and reporting of
the numbers randomized in Results sections significantly
declined in CC, significantly declined, between the two
periods. Reporting of outcomes in Results sections sig-
nificantly improved in AJRCCM and CCM. Reporting
of trial registration in AJRCCM, CCM, and ICM signifi-
cantly improved, with the increase in AJRCCM being
the greatest. A tremendous increase in reporting of
funding in AJRCCM was observed.
Discussion
The findings of our study suggest that, compared with
the pre-CONSORT period, reporting of some items
(title, primary outcomes in both Methods and Results,
interventions, harms, trial registration, funding) in ab-
stracts of critical care trials was improved in the post-
CONSORT period. We examined 18 items in the main
analysis; when the significance threshold was adjusted
with the Bonferroni correction (p < 0.003), significant
improvement in reporting the same items (except inter-
ventions) was still noted. However, even in the post-
CONSORT period, more than 50% of trials inadequately
reported trial design, participants, and outcomes in the
Methods section; randomization procedures, details of
blinding, numbers of participants randomized to each
group, trial status, numbers of participants analyzed in
each group, and outcomes in the Results section; and
adverse effects, trial registrations, and funding. This ten-
dency was generally observed across the four journals,
although there were some small exceptions and varia-
tions. Overall adherence to the CONSORT for abstract
guideline was thus considered suboptimal.
Our results were broadly similar to those of previous
studies [15–17]. Can et al. assessed abstracts of trials
published in four leading anesthesia journals and found
that the quality of reporting abstracts was improved in
the post-CONSORT period (2008 to 2009) compared
with the pre-CONSORT period (2006 to 2007). Adher-
ence to the CONSORT for abstract guideline was only
35.2% even in the post-CONSORT period [15]. Ghimire
et al. investigated whether the overall quality of oncology
trial abstracts was improved in the post-CONSORT
period (2010 to 2012) compared with the pre-CONSORT
period (2005 to 2007), and they found that adherence
to the CONSORT for abstract guideline remained sub-
optimal (55.2%) [14]. Fleming et al. suggested that the
reporting quality of trial abstracts published in leading
orthodontic journals did not change significantly be-
tween the two periods of 2006–2008 and 2009–2011
[19]. Mbuagbaw et al. examined 100 randomly selected
trials published in each of 2007 and 2012 in six leading
general medicine journals (New England Journal of
Table 2 Characteristics of included abstracts from both periods
Pre-CONSORT Post-CONSORT p Value




Trial design 22.7 16.3 0.130
Methods
Participants 41.1 44.0 0.58
Settinga 41.1 44.0 0.58
Interventions 92.4 81.9 0.003
Objective 93.5 95.2 0.50
Outcome 31.4 49.4 0.001
Randomization 1.1 1.8 0.57
Blinding (masking) 3.2 4.2 0.63
Results
Number randomized 41.6 37.4 0.41
Recruitment 2.7 4.2 0.44
Number analyzed 4.3 8.4 0.113
Outcome 4.9 16.9 <0.001
Effect sizea 4.9 20.5 <0.001
Harms 11.9 27.7 <0.001
Conclusion 97.3 97.0 0.86
Trial registration 13.5 42.2 <0.001
Funding 1.6 13.9 <0.001
CONSORT Consolidated Standards of Reporting Trials, N/A not applicable
Data are percentages representing the proportion of abstracts that adhered
to the CONSORT guideline for abstracts
aThese items were additionally examined in this study
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Medicine, Lancet, BMJ, JAMA, Annals of Internal
Medicine, CMAJ) [17]. Abstracts in these journals
tended to report the title (66%), trial design (59%), and
Methods section except randomization and blinding
(about 60% or more), whereas in 2007 they tended to
underreport numbers randomized (53%) and analyzed
(26%), recruitment (25%), harms (53%) in the Results
section, Conclusions section (22%), and funding (0%).
In 2012, in contrast, most items were more frequently
reported than in 2007, but randomization (13%) and
blinding (59%) in the Methods section, numbers ran-
domized (61%), recruitment (49%), harms (60%) in the
Results section, and Conclusions section (26%) remained
lower than the other items. Significant improvements
were seen in the title, trial design, participants, objec-
tives, randomization, and blinding in the Methods sec-
tion, as well as recruitment and numbers analyzed in the
Results section and funding (p < 0.05). Overall, all items
except interventions and objectives in the Methods and
Conclusions sections were much less frequently re-
ported in critical care journals than in leading general
medicine journals. In contrast to general medicine jour-
nals, significant improvement was observed in different
items, except the title and funding in critical care trial
abstracts. Hays et al. examined RCT abstracts published
in five leading general medical journals (New England
Journal of Medicine, Lancet, BMJ, JAMA, Annals of
Internal Medicine) from 2011 to 2014 and suggested
that there was still low adherence to the guideline (over-
all adherence 67%) [20].
The proportion of adequate reporting of interventions
declined significantly between the two periods in our
study (pre-CONSORT 92.4%, post-CONSORT 81.9%). A
similar trend was also observed in two previous studies,
with varying significance [15, 17]. This might have been
due to declines in some, if not all, journals, but reasons
were not possible to elucidate in any of these cases.
Previous studies have also suggested that trials pub-
lished after the announcement of the CONSORT for
abstract guideline tended to inadequately report title,
trial design, and primary outcomes in Methods sections,
randomization procedures, details of blinding, numbers
of patients randomized and analyzed in each group, trial
status, and primary outcomes in Results sections, trial
registration, and funding [5, 7–10, 14–17, 19]. These
tendencies were confirmed in our study.
There are several hypotheses regarding the suboptimal
adherence of critical care journals to the guideline. One
is that the authors were unaware of the CONSORT
guideline for abstracts in the first place. They might
prefer to concentrate their efforts on the manuscripts, or
the adherence to the guideline for abstracts could be felt
to be extra “work” for the authors [21]. Specifically
regarding the harms, critical care trials often examine
undesirable outcomes such as mortality, and harms
could be omitted from the abstracts [17]. Also, when the
intervention of interest was found be effective, it is im-
aginable that the harms were not discussed as well.
One potential argument is that these abstracts under-
reported important information owing to the space
constraints set by journals. Currently, none of the four
journals we selected endorse the CONSORT guideline
for abstracts. The word limits for each journal were as
follows: AJRCCM, 250 words; CCM, 300 words; ICM,
250 words; and CC, 350 words. However, the explanation
and elaboration of the CONSORT guideline for abstracts
considered that items in the checklist could be incorpo-
rated within a limit of 250–300 words [4]. Hopewell et
al. suggested that implementing the CONSORT guide-
line for abstracts led to improvements in the reporting
of trial abstracts in their interrupted time-series analysis
of major general medicine journals [22]. Endorsing the
CONSORT checklist as a journal policy is also known to
be associated with improved reporting of trials [23].
Thus, first of all, it is desirable for editors of critical care
journals to consider adopting the CONSORT guideline
for abstracts as a journal editorial policy as a prerequisite
of submission. This would facilitate adoption of the
CONSORT guideline for abstracts by authors of trial
manuscripts, making abstracts sound and readable. Like-
wise for reviewers, completeness and efficiency of asses-
sing abstracts could be improved if the CONSORT
guideline for abstracts were better disseminated.
Our study has some strengths. We included a large
number of critical care trial abstracts. Two reviewers inde-
pendently evaluated each item of the checklist proposed
by the CONSORT guideline for abstracts in a standardized
manner. This represents one of few studies to assess ad-
herence to the CONSORT guideline for abstracts, along
with changes in the quality of reporting for trial abstracts
between two periods in any domain of medicine.
On the other hand, some limitations must be consid-
ered. First, we focused on only four leading journals,
which may well have been unrepresentative of the totality
of critical care medicine journals. Currently, 27 journals
are listed in the field of critical care medicine by Thomson
Reuters, and the four journals we selected are ranked
among the top five according to impact factor. A previous
study suggested that lower impact factors were associated
with lower quality of reporting abstracts [16]. The report-
ing quality of abstracts in other journals would thus be
expected to be lower than our findings, meriting further
assessment of other critical care journals. Second, a few
years have passed since the second study period in our
investigation. The trial abstracts published in five leading
general medical journals from 2011 to 2014 still showed
low adherence to the guideline (overall adherence 67%)
[20], and thus an update for each area is warranted. To
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our knowledge, the present study is the first one to exam-
ine adherence to the CONSORT guideline for abstracts in
critical care journals. This study thus should serve as the
foundational investigation for the update on the same
topic in critical care medicine and other areas. Third, no
clear consensus or validated methods were seen regarding
the assessment of quality for trial abstracts. Previous stud-
ies have assessed abstracts by each item of the CONSORT
guideline for abstracts [7, 8, 12, 14, 15], measured overall
quality by counting the number of items reported ad-
equately [16, 17], or used their own criteria [9, 10, 19].
However, whether each item can be weighted equally is
questionable. Even so, these studies consistently reported
similar results and inadequately reported items, support-
ing our methods of assessment.
Conclusions
Our findings suggest that the reporting quality of ab-
stracts in critical care journals has improved since the
announcement of the CONSORT guideline for abstracts.
However, overall adherence to the guideline remains
suboptimal. Given the lack of editorial policy to imple-
ment the guideline in critical care journals, journal
editors need to require authors to follow the guideline
to promote further improvements in the quality of
reporting for abstracts and subsequent readability.
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